Solaf Al Awadhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Solaf Al Awadhi has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Amy D. Waterman
J.C. Walter Jr. Transplant Center, Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA
2 shared publications - David A. Axelrod
Department of Surgery, University Hospitals System, Cleveland, Ohio
2 shared publications Eugene P. Rhee
Massachusetts General Hospital, Boston, Massachusetts
2 shared publicationsRanjani N. Moorthi
Indiana University School of Medicine, Indianapolis, Indiana
2 shared publications- Sharon M. Moe
Indiana University School of Medicine, United States
2 shared publications A. L. Jonathan Gelfond
Department of Population Health University of Texas Health Science Center San Antonio Texas USA
1 shared publication
Latest Publications
- 2 March 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (8) , 1210-1214
Fight songs: Why transplant patients battling for life deserve positive anthems, too
Music has long been used to motivate athletes and soldiers, yet transplant patients—who face some of life’s most profound physical and emotional battles—rarely choose positive anthems to motivate themselves. As a liver transplant recipient and peer-support facilitator with the Transplant Recipients International Organization (TRIO), I have witnessed how personal “fight songs” help patients reclaim strength, identity, and hope during recovery. Drawing from the experiences of 10 transplant recipients who shared their fight songs and the meanings behind them, we explored how music fosters resilience and coping throughout the transplant journey. Patients described their songs as lifelines during isolation, dialysis, or recovery—reminders that they were “still breathing,” “still standing,” and “still fighting.” A word-cloud analysis of recurring lyrics revealed shared themes of survival, gratitude, and renewal. These songs were not about illness, but about transcendence. Incorporating discussions of music and meaning into transplant care may humanize the medical experience and strengthen emotional recovery. Selecting a fight song can be another tool that healthcare providers recommend to empower transplant patients.
- 2 March 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (8) , 1210-1214
Fight songs: Why transplant patients battling for life deserve positive anthems, too
Music has long been used to motivate athletes and soldiers, yet transplant patients—who face some of life’s most profound physical and emotional battles—rarely choose positive anthems to motivate themselves. As a liver transplant recipient and peer-support facilitator with the Transplant Recipients International Organization (TRIO), I have witnessed how personal “fight songs” help patients reclaim strength, identity, and hope during recovery. Drawing from the experiences of 10 transplant recipients who shared their fight songs and the meanings behind them, we explored how music fosters resilience and coping throughout the transplant journey. Patients described their songs as lifelines during isolation, dialysis, or recovery—reminders that they were “still breathing,” “still standing,” and “still fighting.” A word-cloud analysis of recurring lyrics revealed shared themes of survival, gratitude, and renewal. These songs were not about illness, but about transcendence. Incorporating discussions of music and meaning into transplant care may humanize the medical experience and strengthen emotional recovery. Selecting a fight song can be another tool that healthcare providers recommend to empower transplant patients.
- Open Access
- 23 September 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 353-361
A Metabolomics Approach To Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance Hemodialysis
Key Points: Uremic symptoms are common in patients with kidney failure, but the chemicals causing them are unknown. We used state-of-the-art untargeted metabolomics and rigorous analyses to search for metabolites associated with uremic symptoms. We identified metabolite-symptom associations but could not replicate findings and offer recommendations for future research. Background: The specific toxins causing uremic symptoms (nausea, vomiting, pruritus, fatigue, difficulty concentrating, and pain) in kidney failure remain unknown. We used untargeted metabolomics to identify plasma metabolites associated with uremic symptoms in patients receiving hemodialysis. Methods: We measured metabolites in plasma samples from Longitudinal US/Canada Incident Dialysis study participants at baseline (discovery; n =636) and year 1 (internal validation; n =260) and from Frailty Assessment in Renal Disease study participants (external validation; n =355). We used metabolite-wise linear models with empirical Bayesian inference to evaluate the association between metabolites and uremic symptom severity, adjusting for key covariates. We accounted for multiple testing using a false discovery rate ( P values adjusted for false discovery rate [pFDR]) for linear models and used two machine learning models to evaluate the association consistency. We defined association as significant if pFDR < 0.1 and consistent if it had medium or high importance in both machine learning models. Results: Participants had a mean age of 63 years, with uremic symptom prevalence ranging from 44% to 83%. We identified 627 previously characterized (known) and 35,558 unknown metabolite peaks. No known metabolites were significantly and consistently associated with uremic symptom severity across all cohorts. Within cohorts, retinol was negatively associated with nausea/vomiting in Longitudinal US/Canada Incident Dialysis at year 1, and indole-3-propionic acid was negatively associated with anorexia in Frailty Assessment in Renal Disease. Several unknown metabolites were associated with symptoms (lowest pFDR, 0.0004), but none were consistent across cohorts. Conclusions: We identified metabolites associated with uremic symptom severity, although findings were inconsistent across cohorts. This study highlights the need for additional research on uremic toxins and clinical outcomes.
- 23 September 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 353-361
Open AccessA Metabolomics Approach To Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance Hemodialysis
Key Points: Uremic symptoms are common in patients with kidney failure, but the chemicals causing them are unknown. We used state-of-the-art untargeted metabolomics and rigorous analyses to search for metabolites associated with uremic symptoms. We identified metabolite-symptom associations but could not replicate findings and offer recommendations for future research. Background: The specific toxins causing uremic symptoms (nausea, vomiting, pruritus, fatigue, difficulty concentrating, and pain) in kidney failure remain unknown. We used untargeted metabolomics to identify plasma metabolites associated with uremic symptoms in patients receiving hemodialysis. Methods: We measured metabolites in plasma samples from Longitudinal US/Canada Incident Dialysis study participants at baseline (discovery; n =636) and year 1 (internal validation; n =260) and from Frailty Assessment in Renal Disease study participants (external validation; n =355). We used metabolite-wise linear models with empirical Bayesian inference to evaluate the association between metabolites and uremic symptom severity, adjusting for key covariates. We accounted for multiple testing using a false discovery rate ( P values adjusted for false discovery rate [pFDR]) for linear models and used two machine learning models to evaluate the association consistency. We defined association as significant if pFDR < 0.1 and consistent if it had medium or high importance in both machine learning models. Results: Participants had a mean age of 63 years, with uremic symptom prevalence ranging from 44% to 83%. We identified 627 previously characterized (known) and 35,558 unknown metabolite peaks. No known metabolites were significantly and consistently associated with uremic symptom severity across all cohorts. Within cohorts, retinol was negatively associated with nausea/vomiting in Longitudinal US/Canada Incident Dialysis at year 1, and indole-3-propionic acid was negatively associated with anorexia in Frailty Assessment in Renal Disease. Several unknown metabolites were associated with symptoms (lowest pFDR, 0.0004), but none were consistent across cohorts. Conclusions: We identified metabolites associated with uremic symptom severity, although findings were inconsistent across cohorts. This study highlights the need for additional research on uremic toxins and clinical outcomes.
- Open Access
- 19 September 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (9) , e70325
Developing and Validating Machine Learning‐Driven Risk Indices to Predict Patient Dropout During Referral, Evaluation, and Waitlisting for Kidney Transplant
Background: Transplant is the optimal treatment for kidney failure; however, disparities in access persist. We developed and validated risk indices to predict early dropout at key stages of the transplant‐seeking process not captured in national registries. Methods: We included patients referred for kidney transplant at Houston Methodist Hospital between June 2016, and November 2023. We collected demographic, clinical, patient‐ and contextual‐level socioeconomic variables from electronic health records and publicly available census data. We used machine learning (ML) models to predict the characteristics of patients at higher risk of dropping out: (1) at referral (before starting evaluation), (2) in the process of evaluation (before waitlisting), and (3) during waitlisting (before receiving a transplant). Model performance was evaluated using AUROC. Results: Of 4133 referred patients, 46% did not attend their first transplant evaluation visit. Of 2414 patients who were medically eligible for transplant and started evaluation, 54% did not become waitlisted. Of 2457 waitlisted patients, 31% became inactive on the waitlist. Higher risk patients were consistently older, obese, and socioeconomically disadvantaged, with stage‐specific differences: social factors—such as being single, unemployed, less educated, and living in high‐deprivation areas—and African American race dominated at referral (AUROC 0.79); clinical comorbidities and both African American and Hispanic ethnicity were prominent at evaluation (AUROC 0.71); and Hispanic ethnicity, smoking, and digital exclusion were key drivers at waitlisting (AUROC 0.76). Conclusion: ML models effectively identified dropout risk at referral, evaluation, and waitlisting, enabling early identification of at‐risk patients. Targeted interventions could reduce disparities, improve evaluation completion, and increase transplant access.
- 19 September 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (9) , e70325
Open AccessDeveloping and Validating Machine Learning‐Driven Risk Indices to Predict Patient Dropout During Referral, Evaluation, and Waitlisting for Kidney Transplant
Background: Transplant is the optimal treatment for kidney failure; however, disparities in access persist. We developed and validated risk indices to predict early dropout at key stages of the transplant‐seeking process not captured in national registries. Methods: We included patients referred for kidney transplant at Houston Methodist Hospital between June 2016, and November 2023. We collected demographic, clinical, patient‐ and contextual‐level socioeconomic variables from electronic health records and publicly available census data. We used machine learning (ML) models to predict the characteristics of patients at higher risk of dropping out: (1) at referral (before starting evaluation), (2) in the process of evaluation (before waitlisting), and (3) during waitlisting (before receiving a transplant). Model performance was evaluated using AUROC. Results: Of 4133 referred patients, 46% did not attend their first transplant evaluation visit. Of 2414 patients who were medically eligible for transplant and started evaluation, 54% did not become waitlisted. Of 2457 waitlisted patients, 31% became inactive on the waitlist. Higher risk patients were consistently older, obese, and socioeconomically disadvantaged, with stage‐specific differences: social factors—such as being single, unemployed, less educated, and living in high‐deprivation areas—and African American race dominated at referral (AUROC 0.79); clinical comorbidities and both African American and Hispanic ethnicity were prominent at evaluation (AUROC 0.71); and Hispanic ethnicity, smoking, and digital exclusion were key drivers at waitlisting (AUROC 0.76). Conclusion: ML models effectively identified dropout risk at referral, evaluation, and waitlisting, enabling early identification of at‐risk patients. Targeted interventions could reduce disparities, improve evaluation completion, and increase transplant access.
- 21 August 2025
- Published by Springer Nature in Current Transplantation Reports
- Vol. 12 (1) , 1-20
Technology-Enabled Remote Patient Monitoring and Education to Improve Kidney Transplant Knowledge, Access, and Post-Transplant Care: A Narrative Review
Purpose of Review Given significant barriers to transplant access and suboptimal post-transplant outcomes, particularly for underserved populations, this review provides a summary of the studies assessing technology-enabled tools for remote patient monitoring (RPM) and education to improve kidney transplant knowledge, access, and care. Drawing on quantitative and qualitative research, we examine how digital health interventions enhance transplant knowledge, adherence, and long-term outcomes while providing recommendations for their effective design and integration into transplant care. Recent Findings Studies demonstrate that technology-enabled interventions, including mobile health applications and personalized educational platforms complemented by provider’s support, improve transplant knowledge, adherence to immunosuppressive therapy, and blood pressure management. Programs also incorporating socio-economic support have been effective in improving transplant knowledge and progression toward transplant among African American and Hispanic patients. Patients value features such as personalized reminders, user-friendly interfaces, and storytelling platforms. However, challenges such as privacy concerns, technology access, and usability remain. Ensuring a patient-centered, culturally, and socioeconomically sensitive approach—while integrating a holistic, multi-level framework that involves patients, caregivers, donors, and healthcare providers and addresses educational, clinical, mental, and social needs—can enhance engagement and health outcomes. Emerging interventions, including wearable biosensors, chatbot-assisted education, artificial intelligence for risk prediction, and remote patient-reported outcome platforms, are expanding transplant care possibilities but require further evaluation, scalability, and centralized integration. Summary Technology-enabled tools offer promising opportunities to address key challenges in kidney transplant care. Future research should focus on scaling, integrating, and optimizing these interventions within a Human Technology Co-Care model, combining digital innovation with provider engagement to ensure equitable, efficient, and patient-centered care.
- 21 August 2025
- Published by Springer Nature in Current Transplantation Reports
- Vol. 12 (1) , 1-20
Technology-Enabled Remote Patient Monitoring and Education to Improve Kidney Transplant Knowledge, Access, and Post-Transplant Care: A Narrative Review
Purpose of Review Given significant barriers to transplant access and suboptimal post-transplant outcomes, particularly for underserved populations, this review provides a summary of the studies assessing technology-enabled tools for remote patient monitoring (RPM) and education to improve kidney transplant knowledge, access, and care. Drawing on quantitative and qualitative research, we examine how digital health interventions enhance transplant knowledge, adherence, and long-term outcomes while providing recommendations for their effective design and integration into transplant care. Recent Findings Studies demonstrate that technology-enabled interventions, including mobile health applications and personalized educational platforms complemented by provider’s support, improve transplant knowledge, adherence to immunosuppressive therapy, and blood pressure management. Programs also incorporating socio-economic support have been effective in improving transplant knowledge and progression toward transplant among African American and Hispanic patients. Patients value features such as personalized reminders, user-friendly interfaces, and storytelling platforms. However, challenges such as privacy concerns, technology access, and usability remain. Ensuring a patient-centered, culturally, and socioeconomically sensitive approach—while integrating a holistic, multi-level framework that involves patients, caregivers, donors, and healthcare providers and addresses educational, clinical, mental, and social needs—can enhance engagement and health outcomes. Emerging interventions, including wearable biosensors, chatbot-assisted education, artificial intelligence for risk prediction, and remote patient-reported outcome platforms, are expanding transplant care possibilities but require further evaluation, scalability, and centralized integration. Summary Technology-enabled tools offer promising opportunities to address key challenges in kidney transplant care. Future research should focus on scaling, integrating, and optimizing these interventions within a Human Technology Co-Care model, combining digital innovation with provider engagement to ensure equitable, efficient, and patient-centered care.
- Open Access
- 29 June 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (9) , 2718-2726
A Metabolomics Approach to Identify Metabolites Associated With Mortality in Patients Receiving Maintenance Hemodialysis
- 29 June 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (9) , 2718-2726
Open AccessA Metabolomics Approach to Identify Metabolites Associated With Mortality in Patients Receiving Maintenance Hemodialysis
- Top Cited Papers
- 6 December 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (2) , 177-188
Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal
Significance Statement: Why are there so few biomarkers accepted by health authorities and implemented in clinical practice, despite the high and growing number of biomaker studies in medical research ? In this meta-epidemiological study, including 804 studies that were critically appraised by expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient monitoring parameters. Most biomarker studies tended to be single-center, retrospective studies with a small number of patients and clinical events. Less than 5% of the studies performed an external validation. The authors also showed the poor transparency reporting and identified a data beautification phenomenon. These findings suggest that there is much wasted research effort in transplant biomarker medical research and highlight the need to produce more rigorous studies so that more biomarkers may be validated and successfully implemented in clinical practice. Background: Despite the increasing number of biomarker studies published in the transplant literature over the past 20 years, demonstrations of their clinical benefit and their implementation in routine clinical practice are lacking. We hypothesized that suboptimal design, data, methodology, and reporting might contribute to this phenomenon. Methods: We formed a consortium of experts in systematic reviews, nephrologists, methodologists, and epidemiologists. A systematic literature search was performed in PubMed, Embase, Scopus, Web of Science, and Cochrane Library between January 1, 2005, and November 12, 2022 (PROSPERO ID: CRD42020154747). All English language, original studies investigating the association between a biomarker and kidney allograft outcome were included. The final set of publications was assessed by expert reviewers. After data collection, two independent reviewers randomly evaluated the inconsistencies for 30% of the references for each reviewer. If more than 5% of inconsistencies were observed for one given reviewer, a re-evaluation was conducted for all the references of the reviewer. The biomarkers were categorized according to their type and the biological milieu from which they were measured. The study characteristics related to the design, methods, results, and their interpretation were assessed, as well as reproducible research practices and transparency indicators. Results: A total of 7372 publications were screened and 804 studies met the inclusion criteria. A total of 1143 biomarkers were assessed among the included studies from blood (n=821, 71.8%), intragraft (n=169, 14.8%), or urine (n=81, 7.1%) compartments. The number of studies significantly increased, with a median, yearly number of 31.5 studies (interquartile range [IQR], 23.8–35.5) between 2005 and 2012 and 57.5 (IQR, 53.3–59.8) between 2013 and 2022 (P < 0.001). A total of 655 studies (81.5%) were retrospective, while 595 (74.0%) used data from a single center. The median number of patients included was 232 (IQR, 96–629) with a median follow-up post-transplant of 4.8 years (IQR, 3.0–6.2). Only 4.7% of studies were externally validated. A total of 346 studies (43.0%) did not adjust their biomarker for key prognostic factors, while only 3.1% of studies adjusted the biomarker for standard-of-care patient monitoring factors. Data sharing, code sharing, and registration occurred in 8.8%, 1.1%, and 4.6% of studies, respectively. A total of 158 studies (20.0%) emphasized the clinical relevance of the biomarker, despite the reported nonsignificant association of the biomarker with the outcome measure. A total of 288 studies assessed rejection as an outcome. We showed that these rejection studies shared the same characteristics as other studies. Conclusions: Biomarker studies in kidney transplantation lack validation, rigorous design and methodology, accurate interpretation, and transparency. Higher standards are needed in biomarker research to prove the clinical utility and support clinical use.
- 6 December 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (2) , 177-188
Top Cited PapersPrognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal
Significance Statement: Why are there so few biomarkers accepted by health authorities and implemented in clinical practice, despite the high and growing number of biomaker studies in medical research ? In this meta-epidemiological study, including 804 studies that were critically appraised by expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient monitoring parameters. Most biomarker studies tended to be single-center, retrospective studies with a small number of patients and clinical events. Less than 5% of the studies performed an external validation. The authors also showed the poor transparency reporting and identified a data beautification phenomenon. These findings suggest that there is much wasted research effort in transplant biomarker medical research and highlight the need to produce more rigorous studies so that more biomarkers may be validated and successfully implemented in clinical practice. Background: Despite the increasing number of biomarker studies published in the transplant literature over the past 20 years, demonstrations of their clinical benefit and their implementation in routine clinical practice are lacking. We hypothesized that suboptimal design, data, methodology, and reporting might contribute to this phenomenon. Methods: We formed a consortium of experts in systematic reviews, nephrologists, methodologists, and epidemiologists. A systematic literature search was performed in PubMed, Embase, Scopus, Web of Science, and Cochrane Library between January 1, 2005, and November 12, 2022 (PROSPERO ID: CRD42020154747). All English language, original studies investigating the association between a biomarker and kidney allograft outcome were included. The final set of publications was assessed by expert reviewers. After data collection, two independent reviewers randomly evaluated the inconsistencies for 30% of the references for each reviewer. If more than 5% of inconsistencies were observed for one given reviewer, a re-evaluation was conducted for all the references of the reviewer. The biomarkers were categorized according to their type and the biological milieu from which they were measured. The study characteristics related to the design, methods, results, and their interpretation were assessed, as well as reproducible research practices and transparency indicators. Results: A total of 7372 publications were screened and 804 studies met the inclusion criteria. A total of 1143 biomarkers were assessed among the included studies from blood (n=821, 71.8%), intragraft (n=169, 14.8%), or urine (n=81, 7.1%) compartments. The number of studies significantly increased, with a median, yearly number of 31.5 studies (interquartile range [IQR], 23.8–35.5) between 2005 and 2012 and 57.5 (IQR, 53.3–59.8) between 2013 and 2022 (P < 0.001). A total of 655 studies (81.5%) were retrospective, while 595 (74.0%) used data from a single center. The median number of patients included was 232 (IQR, 96–629) with a median follow-up post-transplant of 4.8 years (IQR, 3.0–6.2). Only 4.7% of studies were externally validated. A total of 346 studies (43.0%) did not adjust their biomarker for key prognostic factors, while only 3.1% of studies adjusted the biomarker for standard-of-care patient monitoring factors. Data sharing, code sharing, and registration occurred in 8.8%, 1.1%, and 4.6% of studies, respectively. A total of 158 studies (20.0%) emphasized the clinical relevance of the biomarker, despite the reported nonsignificant association of the biomarker with the outcome measure. A total of 288 studies assessed rejection as an outcome. We showed that these rejection studies shared the same characteristics as other studies. Conclusions: Biomarker studies in kidney transplantation lack validation, rigorous design and methodology, accurate interpretation, and transparency. Higher standards are needed in biomarker research to prove the clinical utility and support clinical use.